Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.59 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10234095 | 0.89 | MAPK14 (0.62) | MAPK14DDR2JAK2MAPK13MAPK12 | |
| SCHEMBL1012616 | 0.89 | MAPK13 (0.66) | MAPK14JAK2MAPK13MAPK12MAPK11 | |
| SCHEMBL378957 | 0.88 | MAPK14 (0.68) | MAPK14DDR2JAK2MAPK13MAPK12 | |
| SCHEMBL1013690 | 0.87 | MAPK13 (0.59) | MAPK14JAK2MAPK13MAPK12MAPK11 | |
| SCHEMBL1012997 | 0.86 | MAPK14 (0.66) | MAPK14DDR2JAK2MAPK13MAPK12 | |
| SCHEMBL1013743 | 0.86 | MAPK14 (0.73) | MAPK14JAK2MAPK13MAPK12MAPK11 | |
| SCHEMBL1793950 | 0.86 | MAPK14 (0.58) | MAPK14JAK2MAPK13MAPK12MAPK11 | |
| Carbamic Acid SCHEMBL1780358 | 0.86 | MAPK13 (0.62) | MAPK14JAK2MAPK13MAPK12MAPK11 | |
| SCHEMBL1013422 | 0.85 | MAPK13 (0.69) | MAPK14JAK2MAPK13MAPK12MAPK11 | |
| SCHEMBL4510455 | 0.84 | MAPK14 (0.57) | MAPK14JAK2MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214545-A1 | Substituted Pyrazolyl Urea Derivatives Useful in the Treatment of Cancer | UMPS, SLC14A1, TP53 | MAPK14 2675/4885DDR2 4718/4885JAK2 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.